Deutsche Bank’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-278,005
| Closed | -$14.4M | – | 4142 |
|
|
2022
Q3 | $14.4M | Buy |
278,005
+199,399
| +254% | +$8.24M | 0.01% | 851 |
|
|
2022
Q2 | $1.95M | Buy |
78,606
+25,901
| +49% | +$571K | ﹤0.01% | 1775 |
|
|
2022
Q1 | $1.32M | Sell |
52,705
-748
| -1% | -$21K | ﹤0.01% | 2174 |
|
|
2021
Q4 | $1.95M | Sell |
53,453
-3,610
| -6% | -$127K | ﹤0.01% | 2007 |
|
|
2021
Q3 | $976K | Sell |
57,063
-72,110
| -56% | -$1.12M | ﹤0.01% | 2628 |
|
|
2021
Q2 | $1.73M | Buy |
129,173
+28,047
| +28% | +$691K | ﹤0.01% | 2362 |
|
|
2021
Q1 | $5.18M | Sell |
101,126
-3,216
| -3% | -$193K | ﹤0.01% | 1525 |
|
|
2020
Q4 | $6.46M | Sell |
104,342
-6,563
| -6% | -$376K | ﹤0.01% | 1232 |
|
|
2020
Q3 | $6.08M | Sell |
110,905
-11,900
| -10% | -$641K | ﹤0.01% | 1180 |
|
|
2020
Q2 | $7.07M | Buy |
122,805
+95,366
| +348% | +$5.19M | 0.01% | 1126 |
|
|
2020
Q1 | $1.1M | Buy |
27,439
+12,416
| +83% | +$527K | ﹤0.01% | 2038 |
|
|
2019
Q4 | $593K | Sell |
15,023
-162,013
| -92% | -$2.84M | ﹤0.01% | 2642 |
|
|
2019
Q3 | $1.2M | Buy |
177,036
+47,650
| +37% | +$358K | ﹤0.01% | 2201 |
|
|
2019
Q2 | $1.2M | Buy |
129,386
+13,560
| +12% | +$157K | ﹤0.01% | 2719 |
|
|
2019
Q1 | $1.61M | Buy |
115,826
+31,481
| +37% | +$360K | ﹤0.01% | 2658 |
|
|
2018
Q4 | $919K | Sell |
84,345
-26,988
| -24% | -$285K | ﹤0.01% | 2952 |
|
|
2018
Q3 | $1.41M | Buy |
111,333
+20,254
| +22% | +$244K | ﹤0.01% | 3084 |
|
|
2018
Q2 | $1.2M | Buy |
91,079
+52,340
| +135% | +$626K | ﹤0.01% | 3300 |
|
|
2018
Q1 | $526K | Sell |
38,739
-148,799
| -79% | -$1.54M | ﹤0.01% | 3677 |
|
|
2017
Q4 | $1.11M | Sell |
187,538
-128,344
| -41% | -$880K | ﹤0.01% | 3129 |
|
|
2017
Q3 | $2.34M | Buy |
315,882
+45,591
| +17% | +$379K | ﹤0.01% | 2430 |
|
|
2017
Q2 | $2.53M | Buy |
270,291
+73,820
| +38% | +$542K | ﹤0.01% | 2399 |
|
|
2017
Q1 | $1.43M | Buy |
196,471
+6,067
| +3% | +$43.7K | ﹤0.01% | 2440 |
|
|
2016
Q4 | $1.41M | Sell |
190,404
-72,895
| -28% | -$525K | ﹤0.01% | 2476 |
|
|
2016
Q3 | $1.59M | Buy |
263,299
+58,855
| +29% | +$278K | ﹤0.01% | 2505 |
|
|
2016
Q2 | $916K | Buy |
204,444
+112,429
| +122% | +$422K | ﹤0.01% | 2957 |
|
|
2016
Q1 | $228K | Buy |
92,015
+34,113
| +59% | +$124K | ﹤0.01% | 3599 |
|
|
2015
Q4 | $467K | Sell |
57,902
-31,271
| -35% | -$221K | ﹤0.01% | 3313 |
|
|
2015
Q3 | $537K | Buy |
89,173
+47,432
| +114% | +$343K | ﹤0.01% | 3323 |
|
|
2015
Q2 | $342K | Buy |
41,741
+41,100
| +6,412% | +$326K | ﹤0.01% | 3615 |
|
|
2015
Q1 | $4K | Sell |
641
-52,542
| -99% | -$411K | ﹤0.01% | 4932 |
|
|
2014
Q4 | $362K | Buy |
53,183
+33,160
| +166% | +$175K | ﹤0.01% | 3901 |
|
|
2014
Q3 | $89K | Sell |
20,023
-44,855
| -69% | -$237K | ﹤0.01% | 4573 |
|
|
2014
Q2 | $377K | Sell |
64,878
-82,280
| -56% | -$462K | ﹤0.01% | 3697 |
|
|
2014
Q1 | $975K | Buy |
147,158
+22,070
| +18% | +$153K | ﹤0.01% | 2877 |
|
|
2013
Q4 | $723K | Buy |
125,088
+49,267
| +65% | +$254K | ﹤0.01% | 2852 |
|
|
2013
Q3 | $420K | Sell |
75,821
-22,725
| -23% | -$246K | ﹤0.01% | 3632 |
|
|
2013
Q2 | $1.39M | Buy |
+98,546
| New | +$1.28M | ﹤0.01% | 2463 |
|
Other funds holding CCXI
Deutsche Bank's CCXI Position: Q4 2022 in Review
Deutsche Bank sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 278,005 shares — an estimated $14.4M sold.
Deutsche Bank first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $14.4M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Deutsche Bank reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Deutsche Bank sold 278,005 ChemoCentryx, Inc. shares in Q4 2022, an estimated $14.4M.
- Deutsche Bank first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Deutsche Bank's ChemoCentryx, Inc. position peaked at $14.4M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Deutsche Bank's 13F filing for Q4 2022, filed 13 Feb 2023.